A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapased or Refractory Chronic Lymphocytic Leukemia.

Trial Profile

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapased or Refractory Chronic Lymphocytic Leukemia.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Navitoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors AbbVie
  • Most Recent Events

    • 10 Jul 2017 Planned End Date changed from 1 Aug 2017 to 30 Aug 2018.
    • 10 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 30 Aug 2018.
    • 07 Apr 2017 Planned End Date changed from 1 Nov 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top